Trial Profile
Evaluate the predicted efficay of raltegravir, elvitegravir and dolutegravir in patients harboring INSTI-associated mutations
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Aug 2018
Price :
$35
*
At a glance
- Drugs Dolutegravir (Primary) ; Elvitegravir (Primary) ; Raltegravir (Primary)
- Indications HIV infections
- Focus Therapeutic Use
- 29 Aug 2018 New trial record
- 27 Jul 2018 Results presented at the 22nd International AIDS Conference